DERCOS DS DANDRUFF TREATMENT OBSERVATIONAL STUDY 2022
1 other identifier
observational
5,131
1 country
1
Brief Summary
The aim of this study is to evaluate the satisfaction / tolerance / cosmeticity of Dercos DS
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2022
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 4, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 29, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
June 29, 2023
CompletedFirst Submitted
Initial submission to the registry
August 4, 2023
CompletedFirst Posted
Study publicly available on registry
August 14, 2023
CompletedAugust 14, 2023
August 1, 2023
12 months
August 4, 2023
August 4, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (32)
Desquamation
Scale (0=absence to 4= very severe)
Baseline
Desquamation
Scale (0=absence to 4= very severe)
Day 28
Desquamation
Scale (0=absence to 4= very severe)
Day 56
Irritation
Scale (0=absence to 4= very severe)
baseline
Irritation
Scale (0=absence to 4= very severe)
Day 28
Irritation
Scale (0=absence to 4= very severe)
Day 56
Erythema
Scale (0=absence to 4= very severe)
baseline
Erythema
Scale (0=absence to 4= very severe)
Day 28
Erythema
Scale (0=absence to 4= very severe)
Day 56
Itching
Scale (0=absence to 10= very severe)
baseline
Itching
Scale (0=absence to 10= very severe)
Day 28
Itching
Scale (0=absence to 10= very severe)
Day 56
Area involved
scale from \<10% to \>90%
baseline
Area involved
scale from \<10% to \>90%
Day 28
Area involved
scale from \<10% to \>90%
Day 56
Tolerance
scale from 0= none to 5=very tolerated
baseline
Tolerance
scale from 0= none to 5=very tolerated
Day 28
Improvement
scale from 0= worse to 5=very clearly improved
Day 28
Improvement
scale from 0= worse to 5=very clearly improved
Day 56
Impact of dandruff on patient
Scale from 0=not bothered at all to 5=very bothered
baseline
Impact of dandruff on patient
Scale from 0=not bothered at all to 5=very bothered
Day 28
Impact of dandruff on patient
Scale from 0=not bothered at all to 5=very bothered
Day 56
Global evaluation by investigator
Scale from 0=not at all satisfactory at all to 4=very satisfactory
Day 28
Global evaluation by investigator
Scale from 0=not at all satisfactory at all to 4=very satisfactory
Day 56
Assessment of hair fiber and quality
scale from 0=worsened to 4=very improved
Day 56
Product respect/protects hair fiber
scale from 0=no, it is now more damaged/dry than before the treatment to 3=Yes, my hair fiber looks/feels better than before the treatment
Day 56
Patient product efficacy satisfaction
questionnare with scale ranging from 0=completely disagree to 5=completely agree
Day 28
Patient product efficacy satisfaction
questionnare with scale ranging from 0=completely disagree to 5=completely agree
Day 56
Patient product acceptability
scale ranging from 0=not satisfied at all to 10=very satisfied
Day 28
Patient product acceptability
scale ranging from 0=not satisfied at all to 10=very satisfied
Day 56
Patient global satisfaction
scale ranging from 0=not satisfied at all to 10=very satisfied
Day 28
Patient global satisfaction
scale ranging from 0=not satisfied at all to 10=very satisfied
Day 56
Interventions
to assess the benefit of Dercos DS in subjects with dandruff
Eligibility Criteria
Subjects with dandruff or seborrheic dermatitis
You may qualify if:
- Patients with dandruff or seborrheic dermatitis
- All hair types
- All ethnicities (Asian, Caucasian, Afro-American, African, Hispanic)
- Including patients with specific occlusion habits (for instance veil use at least 8 hours per day, hat use)
- Patients willing to provide written informed consent
You may not qualify if:
- Under 12 years old
- Pregnancy, breast feeding, childbearing potential without adequate contraception, or irregular menstrual cycles.
- History of allergy, anaphylaxis or hypersensitivity to any of the ingredients of Shampoo any of the ingredients of DERCOS ANTI-DANDRUFF normal to oily hair shampoo
- History of allergic contact dermatitis secondary to shampoo, conditioner, mask, and/or leave-in.
- Has any clinical manifestations in the treatment(s) or other disorders that, in the opinion of the investigator, may affect the evaluations or results of the study products.- Inability to stay the study period (56 days +-5 days) without performing any hair/scalp procedure, including coloring, straightening and cutting.
- Inability to attend all study visits and follow treatment regimen
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Marta Sar Pormian
Warsaw, Poland
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 4, 2023
First Posted
August 14, 2023
Study Start
July 4, 2022
Primary Completion
June 29, 2023
Study Completion
June 29, 2023
Last Updated
August 14, 2023
Record last verified: 2023-08
Data Sharing
- IPD Sharing
- Will not share